The Art of Investing Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The Art of Investing

PICK 51.06

+2.3%

Dec 22 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Sun Tzu	10/29/2025 4:54:35 PM
	Read Replies (1) of 10712

Emergent BioSolutions Q3 revenue beats guidance, raises full-year outlook Oct 29, 2025, 16:32 GMT-4Refinitiv1 min read EBS-0.74% Overview Emergent BioSolutions Q3 2025 revenue beats its guidance by $21 mln Adjusted EBITDA for Q3 2025 beats analyst expectations, per LSEG data Company raises full-year 2025 revenue and profitability guidance Outlook Emergent raises 2025 revenue guidance to $775 mln - $835 mln Company revises 2025 net income forecast to $60 mln - $75 mln Emergent increases 2025 adjusted EBITDA guidance to $195 mln - $210 mln Result Drivers NALOXONE SALES - Decrease in Naloxone revenues driven by unfavorable price and volume mix, offset by KLOXXADO sales increase ANTHRAX MCM SALES - Decline in Anthrax MCM revenues due to timing of USG and international sales SMALLPOX MCM SALES - Decrease in Smallpox MCM revenues due to lower USG sales, partially offset by increased international sales

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next